Investigation Into MacroGenics Announced by Hagens Berman

MGNX Stock  USD 3.50  0.11  3.24%   
Slightly above 55% of MacroGenics' investors are presently thinking to get in. The analysis of overall sentiment of trading MacroGenics stock suggests that some investors are interested at this time. MacroGenics' investing sentiment can be driven by a variety of factors including economic data, MacroGenics' earnings reports, geopolitical events, and overall market trends.
  
SAN FRANCISCO, July 19, 2024 -- Hagens Berman urges MacroGenics, Inc. investors who suffered substantial losses to submit your losses now. Visit www.hbsslaw.cominvestor-fraudmgnx

Read at benzinga.com
benzinga news
  

MacroGenics Fundamental Analysis

We analyze MacroGenics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MacroGenics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MacroGenics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Cash Per Share

Cash Per Share Comparative Analysis

MacroGenics is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

MacroGenics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MacroGenics stock to make a market-neutral strategy. Peer analysis of MacroGenics could also be used in its relative valuation, which is a method of valuing MacroGenics by comparing valuation metrics with similar companies.

Peers

MacroGenics Related Equities

CCCCC4 Therapeutics   13.33   
0%
100.0%
MLYSMineralys Therapeutics,   8.10   
0%
60.0%
GLUEMonte Rosa   6.57   
0%
49.0%
IPSCCentury Therapeutics   6.29   
0%
47.0%
CGEMCullinan Oncology   4.98   
0%
37.0%
ZNTLZentalis Pharmaceuticals   4.79   
0%
35.0%
TYRATyra Biosciences   3.69   
0%
27.0%
INZYInozyme Pharma   3.63   
0%
27.0%
EWTXEdgewise Therapeutics   3.23   
0%
24.0%
DAWNDay One   2.15   
0%
16.0%
PEPGPepGen   1.42   
0%
10.0%
SNDXSyndax Pharmaceuticals   1.25   
0%
9.0%
PTGXProtagonist Therapeutics   0.91   
0%
6.0%
ANTXAN2 Therapeutics   0.69   
5.0%
0%
MOLNMolecular Partners   1.55   
11.0%
0%
KZRKezar Life   2.16   
16.0%
0%
NKTXNkarta   2.27   
17.0%
0%
PHVSPharvaris   2.31   
17.0%
0%
PMVPPmv Pharmaceuticals   5.36   
40.0%
0%

Additional Tools for MacroGenics Stock Analysis

When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.